Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2001-11-0067.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2001-11-0067v1
100/4/1133    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, B. D
Right arrow Articles by Lillicrap, D. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, B. D
Right arrow Articles by Lillicrap, D. P
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted November 28, 2001
Accepted March 29, 2002

Dangerous Liaisons: The Role of 'Danger' Signals in the Immune Response to Gene Therapy

Brian D Brown and David P Lillicrap*

Department of Pathology, Queen's University, Kingston, Ontario, Canada

* Corresponding author; email: lillicrap{at}cliff.path.queensu.ca.

Recent studies in gene transfer suggest the innate immune system plays a significant role in impeding gene therapy. In this review, we examine factors that might influence the recruitment and activation of the innate system in the context of gene therapy. We have adopted a novel model of immunology which contends that the immune system does not distinguish between self and non-self, but what is dangerous and what is not dangerous. In taking this perspective, we provide an alternative and complementary insight into some of the failures and successes of current gene therapy protocols.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
B. D. Brown, A. Cantore, A. Annoni, L. S. Sergi, A. Lombardo, P. Della Valle, A. D'Angelo, and L. Naldini
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Blood, December 15, 2007; 110(13): 4144 - 4152.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. S. Cameron, L. Alexopoulou, J. A. Sloane, A. B. DiBernardo, Y. Ma, B. Kosaras, R. Flavell, S. M. Strittmatter, J. Volpe, R. Sidman, et al.
Toll-Like Receptor 3 Is a Potent Negative Regulator of Axonal Growth in Mammals
J. Neurosci., November 21, 2007; 27(47): 13033 - 13041.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Lillicrap
Inducing Tregs with hepatic gene therapy
Blood, August 15, 2007; 110(4): 1089 - 1089.
[Full Text] [PDF]


Home page
Cancer Res.Home page
A. Wallace, D. F. LaRosa, V. Kapoor, J. Sun, G. Cheng, A. Jassar, A. Blouin, L.-M. Ching, and S. M. Albelda
The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes
Cancer Res., July 15, 2007; 67(14): 7011 - 7019.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D.-A. Gross, P. Chappert, M. Leboeuf, V. Monteilhet, L. Van Wittenberghe, O. Danos, and J. Davoust
Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products
Blood, September 15, 2006; 108(6): 1841 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
E. Dobrzynski and R. W. Herzog
Tolerance Induction by Viral In Vivo Gene Transfer
Clin. Med. Res., November 1, 2005; 3(4): 234 - 240.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Follenzi, M. Battaglia, A. Lombardo, A. Annoni, M. G. Roncarolo, and L. Naldini
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice
Blood, May 15, 2004; 103(10): 3700 - 3709.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. D. Brown, C. X. Shi, S. Powell, D. Hurlbut, F. L. Graham, and D. Lillicrap
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
Blood, February 1, 2004; 103(3): 804 - 810.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Kochling, S. A. Konig-Merediz, R. Stripecke, D. Buchwald, A. Korte, H. G. von Einsiedel, F. Sack, G. Henze, K. Seeger, B. Wittig, et al.
Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral, Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides
Clin. Cancer Res., August 1, 2003; 9(8): 3142 - 3149.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle
Side effects of retroviral gene transfer into hematopoietic stem cells
Blood, March 15, 2003; 101(6): 2099 - 2113.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020